The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.

Study Design: Parallel Assignment, Safety/Efficacy Study

Intervention: Dabigatran etexilate vs. Warfarin

Length of Study: 6 years

# of Patients: 18,000

Patient Populations: Atrial fibrillation.

Presentations

Not available at this time.

Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)